natgillin/translations-raw huggingface dataset:
An outcome study has not been conducted with nateglinide, therefore the long-term benefits associated with improved glycaemic control have not been demonstrated. 
Z nateglinidom ni bila opravljenja študija izida, zato niso dokazane dolgoročne koristi, povezane z izboljšanim uravnavanjem koncentracije glukoze v krvi.
Do not take a double dose of Trazec to make up for the one that you missed. 
Ne vzemite dvojnega odmerka Trazeca, da bi nadomestili izpuščenega.
• Type 1 diabetes (insulin-dependent diabetes mellitus, C-peptide negative) 
• s sladkorno boleznijo tipa 1 (od insulina odvisna, na C-peptid negativna sladkorna bolezen);
Trazec tablets start to act quickly after you take them and are eliminated from the body rapidly. 
Tablete Trazeca začnejo delovati kratek čas po zaužitju in se hitro izločijo iz telesa.
The recommended starting dose is 60 mg three times daily before meals, particularly in patients who are near goal HbA1c. 
Priporočeni začetni odmerek je 60 mg trikrat na dan pred obroki, posebno pri bolnikih, pri katerih je glikozilirani hemoglobin (HbA1c) blizu ciljnemu.
Always take Trazec exactly as your doctor has told you. 
Jemljite Trazec, kot vam je naročil zdravnik.
However, an overdose may result in an exaggerated glucose-lowering effect, with the development of hypoglycaemic symptoms. 
Lahko pa prevelik odmerek povzroči pretiran hipoglikemični učinek z razvojem hipoglikemičnih simptomov.
In a clinical study in patients, Trazec was administered in increasing doses up to 720 mg a day for 7 days and was well tolerated. 
V klinični študiji so bolniki prejeli Trazec v naraščajočih odmerkih do 720 mg na dan 7 dni dolgo in so ga bolniki dobro prenašali.
Dose adjustments should be based on periodic glycosylated haemoglobin (HbA1c) measurements. 
Prilagoditve odmerjanja morajo temeljiti na periodičnih meritvah glikoziliranega hemoglobina (HbA1c).
For any information about this medicinal product, please contact the local representative of the 
Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika dovoljenja za promet z zdravilom:
In type 2 diabetic patients, the insulinotropic response to a meal occurs within the first 15 minutes following an oral dose of nateglinide. 
Pri bolnikih s sladkorno boleznijo tipa 2 se insulinotropni odgovor na obrok pojavi v prvih 15 minutah po peroralnem odmerku nateglinida.
Its effect is dependent on functioning beta cells in the pancreas islets. 
Njegov učinek je odvisen od delujočih celic beta v otočkih trebušne slinavke.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. 
Če vam je zdravnik povedal, da ne prenašate nekaterih sladkorjev, se pred jemanjem tega zdravila posvetujte s svojim zdravnikom.
In patients with type 2 diabetes, the body may not start producing insulin quickly enough after meals. 
Pri bolnikih s sladkorno boleznijo tipa 2 telo po zaužitju hrane ne začne izdelovati insulina dovolj hitro.
Do not breast-feed during treatment with Trazec. 
Med zdravljenjem s Trazecom ne dojite.
When given post-prandially, the extent of nateglinide absorption (AUC) remains unaffected. 
Jemanje nateglinida po obroku ne vpliva na obseg njegove absorpcije (AUC).
Medicines, including Trazec, may also produce symptoms of low blood sugar. 
Zdravila, med drugim Trazec, utegnejo tudi povzročiti simptome nizkega krvnega sladkorja.
Plasma concentrations decline rapidly and the elimination half-life of nateglinide typically averaged 1.5 hours in all studies of Trazec in volunteers and type 2 diabetic patients. 
Plazemske koncentracije se hitro zmanjšujejo in razpolovni čas odstranjevanja nateglinida iz telesa je bil povprečno 1,5 ure, kar je bilo značilno za vse študije Trazeca pri prostovoljcih in bolnikih s sladkorno boleznijo tipa 2.
The efficacy of nateglinide in combination with metformin has been compared to the combination of gliclazide plus metformin in a 6-month randomised, double-blind trial in 262 patients using a superiority design. 
Učinkovitost nateglinida v kombinaciji z metforminom so primerjali s kombinacijo gliklazida plus metformina v 6-mesečnem randomiziranem, dvojno slepem preskusu pri 262 bolnikih z uporabo zasnove z namenom dokazovanja večje primernosti zdravila.
In vitro studies show that nateglinide is extensively bound (97-99%) to serum proteins, mainly serum albumin and to a lesser extent alpha1-acid glycoprotein. 
Raziskave in vitro kažejo, da se nateglinid v zelo veliki meri (97-99 %) veže na serumske beljakovine, predvsem na serumske albumine in v manjši meri na α1-kisli glikoprotein.
Blisters: PVC/PE/PVDC moulded foil with aluminium lidding foil. 
Pretisni omoti: odtisnjena folija iz PVC/PE/PVDC z aluminijasto prekrivno folijo.
Symptoms of hypoglycaemia (unconfirmed by blood glucose levels) were observed in patients whose baseline HbA1c was close to the therapeutic target (HbA1c <7.5%). 
Simptomi hipoglikemije (ki ni bila potrjena s koncentracijami glukoze v krvi) so bili opazovani pri bolnikih, katerih izhodiščni HbA1c je bil blizu terapevtske tarče (HbA1c < 7,5 %).
Severe hypoglycaemic reactions with coma, seizure or other neurological symptoms should be treated with intravenous glucose. 
Težke hipoglikemične reakcije s komo, napadi krčev ali drugimi nevrološkimi simptomi je treba zdraviti z intravensko glukozo.
Packs contain 12, 60, 84, 120 and 360 tablets. 
Škatle vsebujejo po 12, 60, 84, 120 in 360 tablet.
The risk of hypoglycaemia in type 2 diabetic patients may be increased by strenuous physical exercise, or ingestion of alcohol. 
Nevarnost hipoglikemije pri bolnikih s sladkorno boleznijo tipa 2 lahko poveča hud telesni napor ali uživanje alkohola.
The usual dose of Trazec to start with is 60 mg before the three main meals. 
Običajni začetni odmerek Trazeca je 60 mg pred tremi glavnimi obroki.
When a patient stabilised on any oral hypoglycaemic agent is exposed to stress such as fever, trauma, infection or surgery, a loss of glycaemic control may occur. 
Kadar je bolnik, ki je stabiliziran na kateremkoli peroralnem hipoglikemičnem sredstvu, izpostavljen stresu, na primer zvišani telesni temperaturi, poškodbi, okužbi ali operaciji, lahko pride do izgube kontrole nad glikemijo.
In debilitated or malnourished patients the initial and maintenance dosage should be conservative and careful titration is required to avoid hypoglycaemic reactions. 
Pri oslabljenih ali podhranjenih bolnikih morata biti začetno in vzdrževalno odmerjanje konzervativna in potrebno je skrbno prilagajanje odmerjanja terapevtskemu učinku, da se preprečijo hipoglikemične reakcije.
Take Trazec daily until your doctor tells you to stop. 
Kako dolgo jemati zdravilo Trazec Jemljite Trazec vsak dan, dokler vam zdravnik ne naroči, da ga prenehajte jemati.
SPECIAL STORAGE CONDITIONS Do not store above 30°C. 
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte pri temperaturi do 30 °C.
Elderly, malnourished patients and those with adrenal or pituitary insufficiency or severe renal impairment are more susceptible to the glucoselowering effect of these treatments. 
Starejši bolniki, podhranjeni bolniki in tisti z insuficienco nadledvičnic ali hipofize ali hudo ledvično okvaro so dovzetnejši za hipoglikemični učinek teh vrst zdravljenja.
The dosage of nateglinide should be determined by the physician according to the patient's 
Odmerjanje nateglinida mora določiti zdravnik v skladu z bolnikovimi potrebami.
Trazec, like other oral antidiabetic agents, is not recommended for use in pregnancy. 
Trazec, podobno kot drugi peroralni antidiabetiki, v nosečnosti ni priporočljiv.
when taken before a meal, restores early or first phase insulin secretion, which is lost in patients with type 2 diabetes, resulting in a reduction in post-meal glucose and HbA1c. 
Če nateglinid vzamemo pred obrokom, spet vzpostavi zgodnjo sekrecijo oziroma prvo fazo sekrecije insulina, ki jo bolniki s sladkorno boleznijo tipa 2 izgubijo, kar ima za posledico znižanje postprandialne glukoze in HbA1c.
Each blister pack contains 12, 60, 84, 120 or 360 tablets. 
Vsako pakiranje pretisnih omotov vsebuje 12, 60, 84, 120 ali 360 tablet.
In type 2 diabetic patients given Trazec over the dose range 60 to 240 mg before three meals per day for one week, nateglinide showed linear pharmacokinetics for both AUC and Cmax, and 
Pri bolnikih s sladkorno boleznijo tipa 2, ki so dobivali Trazec v mejah odmerkov od 60 do 240 mg pred tremi obroki na dan en teden dolgo, je nateglinid kazal linearno farmakokinetiko tako za AUC kot za Cmax, tmax pa je bil od odmerka neodvisen.
Conversely, these medicinal products had no effect on the pharmacokinetics of nateglinide. 
Obratno ta zdravila niso vplivala na farmakokinetiko nateglinida.
It is usually taken immediately (1 minute) before a meal but may be taken up to 30 minutes before meals. 
Navadno ga bolniki jemljejo tik (1 minuto) pred obrokom, lahko pa tudi do 30 minut pred obroki.
Nateglinide is rapidly and almost completely (≥ 90%) absorbed from an oral solution. 
Iz peroralne raztopine se nateglinid absorbira hitro in skoraj popolnoma (≥ 90 %).
Nateglinide efficacy was inferior to that of metformin in monotherapy (decrease in HbA1c (%) with metformin 500 mg three times daily monotherapy: -1.23 [95% CI: -1.48; -0.99] and with nateglinide 120 mg three times daily monotherapy -0.90 [95% CI: -1.14; -0.66]). 
Učinkovitost nateglinida je bila slabša od učinkovitosti metformina v okviru monoterapije (znižanje HbA1c (%) pri monoterapiji z metforminom 500 mg trikrat na dan: -1,23 [95 %-ni interval zaupanja:1,48; -0,99] in pri monoterapiji z nateglinidom 120 mg trikrat na dan -0,90 [95 %-ni interval zaupanja: -1,14; -0,66]).
Hypoglycaemic symptoms without loss of consciousness or neurological findings should be treated with oral glucose and adjustments in dosage and/or meal patterns. 
Hipoglikemične simptome brez izgube zavesti ali nevroloških znakov je treba zdraviti s peroralno glukozo in prilagajanjem odmerjanja in/ali vzorcev obrokov.
In an interaction trial with sulfinpyrazone, a CYP2C9 inhibitor, a modest increase in nateglinide AUC (~28%) was observed in healthy volunteers, with no changes in the mean Cmax and elimination half-life. 
V preskušanju interakcij z inhibitorjem CYP2C9 sulfinpirazonom je bil pri zdravih prostovoljcih opažen zmeren porast AUC nateglinida (~28 %), brez sprememb srednje Cmax in razpolovnega časa izločanja iz telesa.
Nateglinide and its metabolites are rapidly and completely eliminated. 
Nateglinid in njegovi presnovki se hitro in popolnoma izločijo iz telesa.
Trazec is contraindicated in patients with: 
Trazec je kontraindiciran pri bolnikih:
Like all medicines, Trazec can cause side effects, although not everybody gets them. 
Kot vsa zdravila ima lahko tudi zdravilo Trazec neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
• Hypersensitivity to the active substance or to any of the excipients 
• s preobčutljivostjo za zdravilno učinkovino ali katerokoli pomožno snov;
Ask your doctor or pharmacist for advice before taking any medicine while you are pregnant or breast 
Posvetujte se z zdravnikom ali s farmacevtom, preden v nosečnosti ali med dojenjem vzamete katerokoli zdravilo.
These symptoms included sweating, trembling, dizziness, increased appetite, palpitations, nausea, fatigue, and weakness. 
Ti simptomi so zajemali znojenje, tresenje, vrtoglavost, povečan tek, palpitacije, navzejo, utrujenost in oslabelost.
Although safety was not compromised in this population dose adjustment may be required in view of low Cmax. 
Čeprav v tej skupini varnost ni bila ogrožena, je lahko potrebno zaradi nizke Cmax prilagoditi odmerek.
Watch carefully for signs of low blood sugar, especially if you have exercised more strenuously than usual. 
Bodite pozorni na znake nizkega krvnega sladkorja, zlasti še - če ste se pri telesni aktivnosti bolj naprezali kot navadno, - če ste pili alkohol.
In completed clinical trials, symptoms of hypoglycaemia were reported in 10.4% with nateglinide monotherapy, 14.5% with nateglinide+metformin combination, 6.9% with metformin alone, 19.8% with glibenclamide alone, 
V končanih kliničnih preskušanjih so o simptomih hipoglikemije poročali pri monoterapiji z nateglinidom pri 10,4 %, pri kombinaciji nateglinida in metformina pri 14,5 %, pri samem metforminu pri 6,9 %, pri samem glibenklamidu pri 19,8 % in pri placebu pri 4,1 %.
The steady-state volume of distribution of nateglinide based on intravenous data is estimated to be approximately 10 litres. 
Ocenjujejo, da je porazdelitveni prostor nateglinida v stanju dinamičnega ravnovesja na podlagi intravenskih podatkov okrog 10 litrov.
No clinical studies have been conducted in patients with severe hepatic impairment or children and adolescents. 
Pri bolnikih s hudo jetrno okvaro ter pri otrocih in mladostnikih niso bile opravljene klinične raziskave.
This is particularly important if you have reduced or absent awareness of the warning signs of hypoglycaemia or if you have frequent episodes of hypoglycaemia. 
To je zlasti pomembno, če se manj ali sploh ne zavedate svarilnih znakov hipoglikemije ali če imate pogoste epizode hipoglikemije.
Consistent with its short elimination half-life, there is no apparent accumulation of nateglinide upon multiple dosing with up to 240 mg three times daily. 
V skladu s kratkim razpolovnim časom se nateglinid po večkratnem odmerjanju z do 240 mg trikrat na dan ne akumulira v telesu.
Trazec and older people Trazec can be used by people over 65 years of age. 
Trazec lahko uporabljajo tudi ljudje, starejši od 65 let.
In combination with metformin, which mainly affected fasting plasma glucose, the effect of nateglinide on HbA1c was additive compared to either agent alone. 
V kombinaciji z metforminom, ki je vplival predvsem na plazemsko glukozo na tešče, je bil učinek nateglinida na HbA1c aditiven, če ga primerjamo z vsako od obeh snovi posebej.
Nateglinide-induced insulin secretion by pancreatic beta cells is glucose-sensitive, such that less insulin is secreted as glucose levels fall. 
Sekrecija insulina iz pankreatičnih celic beta, ki jo povzroči nateglinid, je občutljiva za glukozo, tako da se izloča manj insulina, ko koncentracija glukoze pada.
If you do get symptoms of low blood sugar, eat or drink something containing sugar and talk to your doctor. 
Če dobite simptome nizkega krvnega sladkorja, pojejte ali popijte nekaj kar vsebuje sladkor in se pogovorite z zdravnikom.
The decrease from baseline in HbA1c was -0.41% in the nateglinide plus metformin group and -0.57% in the gliclazide plus metformin group (difference 0.17%, [95% CI -0.03, 0.36]). 
HbA1c se je zmanjšal od izhodišča za0,41 % v skupini z nateglinidom plus metforminom in za -0,57 % v skupini z gliklazidom plus metforminom (razlika 0,17 %, [95-odstotni interval zaupanja -0,03, 0,36]).
Patients should be advised to take precautions to avoid hypoglycaemia whilst driving or operating machinery. 
Bolnikom morate svetovati, naj se s previdnostnimi ukrepi izognejo hipoglikemiji tačas ko vozijo ali upravljajo s stroji.
Insulin levels return to baseline within 3 to 4 hours, reducing post-meal 
Koncentracija insulina se vrne na izhodiščno vrednost v 3 do 4 urah, kar zmanjša postprandialno hiperinsulinemijo.
Nateglinide is rapidly absorbed following oral administration of Trazec tablets prior to a meal, with mean peak drug concentration generally occurring in less than 1 hour. 
Nateglinid se po peroralnem zaužitju tablet Trazec pred obrokom hitro absorbira, povprečna najvišja koncentracija zdravila se običajno pojavi v manj kot 1 uri.
Nateglinide is indicated for combination therapy with metformin in type 2 diabetic patients inadequately controlled despite a maximally tolerated dose of metformin alone. 
Nateglinid je indiciran za kombinirano zdravljenje z metforminom pri bolnikih s sladkorno boleznijo tipa 2, ki niso ustrezno kontrolirani kljub največjemu odmerku metformina samega, ki ga lahko prenašajo.
Based on the experience with nateglinide and with other hypoglycaemic agents, the following adverse reactions have been seen. 
Na podlagi izkušenj z nateglinidom in drugimi hipoglikemičnimi sredstvi so bili ugotovljeni spodaj navedeni neželeni učinki.
Your doctor will determine the dosage you require. 
Vaš zdravnik bo določil odmerjanje, ki je za vas najbolj primerno.
Early insulin secretion is a mechanism for the maintenance of normal glycaemic control. 
Zgodnja sekrecija insulina je mehanizem za vzdrževanje normalnega uravnavanja koncentracije glukoze v krvi.
Patients with rare hereditary problems of galactose intolerance, of the Lapp lactase deficiency or of glucose-galactose malabsorption should not take this medicine. 
Bolniki z redkimi prirojenimi motnjami kot so intoleranca za galaktozo, laponska oblika zmanjšane aktivnosti laktaze ali malabsorpcija glukoze/galaktoze, ne smejo jemati tega zdravila.
A very rare effect is skin rash with blisters affecting the lips, eyes, mouth, sometimes with headache, 
Zelo redek učinek je kožni izpuščaj z mehurčki na ustnicah, očeh in v ustih, včasih z glavobolom, zvišano telesno temperaturo in/ali drisko.
If you do get symptoms of low blood sugar, eat or drink something containing sugar. 
Če dobite simptome nizkega krvnega sladkorja, pojejte ali popijte nekaj kar vsebuje sladkor.
Since the primary therapeutic effect of Trazec is to reduce mealtime glucose, (a contributor to HbA1c), the therapeutic response to Trazec may also be monitored with 1-2 hour post-meal glucose. 
Ker je primarni terapevtski učinek Trazeca zniževanje glukoze v času obroka (ki je eden od dejavnikov, ki prispevajo k HbA1c), lahko terapevtski odziv na Trazec spremljamo tudi z glukozo 1-2 uri po obroku.
The extent of serum protein binding is independent of drug concentration over the test range of 0.1-10 μg Trazec/ml. 
Stopnja vezave na serumske beljakovine je v mejah testiranja od 0,1 do 10 µg Trazeca/ml neodvisna od koncentracije zdravila.
Nateglinide has shown a low potential for protein displacement in in vitro studies. 
V raziskavah in vitro je nateglinid pokazal le majhen potencial za izpodrivanje beljakovin.
If you have accidentally taken too many tablets, talk to a doctor straight away. 
Če ste vzeli večji odmerek zdravila Trazec, kot bi smeli Če ste pomotoma vzeli preveč tablet, se nemudoma posvetujte z zdravnikom.
This is particularly important in those who have reduced or absent awareness of the warning signs of hypoglycaemia or have frequent episodes of hypoglycaemia. 
To je posebno pomembno za tiste, ki se manj ali sploh ne zavedajo svarilnih znakov hipoglikemije ali imajo pogoste epizode hipoglikemije.
This results in a blood-glucose-lowering effect throughout the meal period. 
To povzroči hipoglikemični učinek, ki traja ves čas obroka.
Nateglinide closes ATP-dependent potassium channels in the beta-cell membrane with characteristics that distinguish it from other sulphonylurea receptor ligands. 
Nateglinid zapira od ATP odvisne kalijeve kanalčke v membrani celice beta z značilnostmi, ki ga ločijo od drugih ligandov za receptorje za sulfonilsečnino.
When these medicinal products are administered to or withdrawn from patients receiving nateglinide, the patient should be observed closely for changes in glycaemic control. 
Kadar so bolniku, ki jemlje nateglinid, predpisana ali ukinjena ta zdravila, ga je treba natančno opazovati glede sprememb glikemične kontrole.
If you get any of these symptoms - feeling dizzy, light-headed, hungry, shaky or any of the other signs in section 4, “Possible side effects” - eat or drink something containing sugar. 
Če dobite enega ali več od teh simptomov - občutek vrtoglavosti, omotičnosti, lakote, tresenje ali kak drug znak iz poglavja 4, “Možni neželeni učinki” - pojejte ali popijte nekaj kar vsebuje sladkor.
As nateglinide is highly protein-bound, dialysis is not an efficient means of 
Ker je nateglinid v veliki meri vezan na beljakovine, dializa ni učinkovito sredstvo za odstranjevanje tega zdravila iz krvi.
Preclinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to fertility and post-natal development. 
Predklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih, genotoksičnosti, kancerogenega potenciala in toksičnosti za plodnost in postnatalni razvoj ne kažejo posebnega tveganja za človeka.
The advisability of driving should be considered in these circumstances. 
V teh okoliščinah je treba pretehtati, ali je upravljanje motornega vozila sploh priporočljivo.
In vivo, nateglinide has no clinically relevant effect on the pharmacokinetics of medicinal products metabolised by CYP2C9 and CYP3A4. 
In vivo nateglinid nima klinično pomembnega učinka na farmakokinetiko zdravil, ki jih presnavljata CYP2C9 in CYP3A4.
• CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON Medicinal product subject to medical prescription 
B. POGOJI DOVOLJENJA ZA PROMET Z ZDRAVILOM • POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE, PREDPISANI IMETNIKU
The systemic availability and half-life in dialysis-dependent diabetic patients was comparable with healthy subjects. 
Sistemska uporabnost in razpolovni čas pri sladkornih bolnikih, odvisnih od dialize, sta bila primerljiva s tistima pri zdravih osebah.
Gender: No clinically significant differences in nateglinide pharmacokinetics were observed between 
Spol: med moškimi in ženskami niso opažene klinično pomembne razlike v farmakokinetiki nateglinida.
Lactose monohydrate: 141.5 mg per tablet. 
Pomožne snovi: laktoza monohidrat: 141,5 mg na tableto.
The resulting calcium influx enhances insulin secretion. 
Posledični vstop kalcija poveča sekrecijo insulina.
Nateglinide is a rapid, short-acting oral insulin secretagogue. 
Nateglinid je hitro in kratkotrajno delujoč peroralen sekretagog insulina.
Renal impairment: The systemic availability and half-life of nateglinide in diabetic patients with mild, moderate (creatinine clearance 31-50 ml/min) and severe (creatinine clearance 15-30 ml/min) renal impairment (not undergoing dialysis) did not differ to a clinically significant degree from those in healthy subjects. 
Ledvična okvara: sistemska uporabnost in razpolovni čas nateglinida pri sladkornih bolnikih z blago, zmerno (očistek kreatinina 31-50 ml/min) in hudo (očistek kreatinina 15-30 ml/min) okvaro ledvic (ki niso na dializi), se nista razlikovala v klinično značilni meri od tistih pri zdravih osebah.
Although there is a 49% decrease in Cmax of nateglinide in dialysis patients, the systemic availability and half-life in diabetic subjects with moderate to severe renal insufficiency (creatinine clearance 15-50 ml/min) was comparable between renal subjects requiring haemodialysis and healthy subjects. 
Čeprav se pri dializnih bolnikih Cmax nateglinida zmanjša za 49 %, sta bila sistemska uporabnost in razpolovni čas pri sladkornih bolnikih z zmerno do hudo ledvično insuficienco (očistek kreatinina 15-50 ml/min) pri ledvičnih bolnikih, ki potrebujejo hemodializo, in pri zdravih osebah primerljiva.
In rabbits, at maternally toxic doses a higher incidence of foetuses with no gallbladder was observed. 
Pri kuncih je bila pri odmerkih, toksičnih za mater, opažena večja pogostost plodov brez žolčnika.
The side effects caused by Trazec are usually mild to moderate. 
Neželeni učinki, ki jih povzroča Trazec, so navadno blagi do zmerni.
Conversely, the coadministration of food or a glucose infusion results in an enhancement of insulin secretion. 
Obratno sočasno dajanje hrane ali infuzije glukoze povzroči povečanje sekrecije insulina.
Rare effects are mild abnormalities in liver function tests and allergic (hypersensitivity) reactions such 
Redki učinki so blage nenormalnosti testov jetrnih funkcij in alergijske (preobčutljivostne) reakcije, na primer izpuščaj in srbenje.
Trazec contains lactose monohydrate. 
Trazec vsebuje laktozo monohidrat.